MX2022006021A - Peg-lipido. - Google Patents

Peg-lipido.

Info

Publication number
MX2022006021A
MX2022006021A MX2022006021A MX2022006021A MX2022006021A MX 2022006021 A MX2022006021 A MX 2022006021A MX 2022006021 A MX2022006021 A MX 2022006021A MX 2022006021 A MX2022006021 A MX 2022006021A MX 2022006021 A MX2022006021 A MX 2022006021A
Authority
MX
Mexico
Prior art keywords
peg
lipid
sulfated glycosaminoglycan
biological tissue
schiff base
Prior art date
Application number
MX2022006021A
Other languages
English (en)
Inventor
Bo Nilsson
Ekdahl Kristina Nilsson
Waern Marianne Jensen
Yuji Teramura
Original Assignee
Icoat Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icoat Medical Ab filed Critical Icoat Medical Ab
Publication of MX2022006021A publication Critical patent/MX2022006021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/0231—Chemically defined matrices, e.g. alginate gels, for immobilising, holding or storing cells, tissue or organs for preservation purposes; Chemically altering or fixing cells, tissue or organs, e.g. by cross-linking, for preservation purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un PEG-lípido se produce mezclando un catión-PEG-lípido que comprende al menos un grupo amino con un glicosaminoglicano sulfatado que comprende al menos un grupo carbonilo para formar un intermediario de base de Schiff. Se añade un agente reductor al intermediario de base de Schiff para formar un glicosaminoglicano sulfatado-PEG-lípido. El glicosaminoglicano sulfatado-PEG-lípido se puede utilizar para tejidos biológicos contra la tromboinflamación. El revestimiento de tejido biológico con el glicosaminoglicano sulfatado-PEG-lípido se puede realizar en un proceso de paso único y no causa alguna agregación celular significativa.
MX2022006021A 2020-01-15 2020-12-08 Peg-lipido. MX2022006021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2050025 2020-01-15
PCT/SE2020/051177 WO2021145807A1 (en) 2020-01-15 2020-12-08 Peg-lipid

Publications (1)

Publication Number Publication Date
MX2022006021A true MX2022006021A (es) 2022-09-07

Family

ID=76864776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006021A MX2022006021A (es) 2020-01-15 2020-12-08 Peg-lipido.

Country Status (11)

Country Link
US (1) US20220401566A1 (es)
EP (1) EP4090375A4 (es)
JP (1) JP2023513656A (es)
KR (1) KR20220127808A (es)
CN (1) CN114761043A (es)
AU (1) AU2020423624A1 (es)
BR (1) BR112022009681A2 (es)
CA (1) CA3157794A1 (es)
IL (1) IL292335A (es)
MX (1) MX2022006021A (es)
WO (1) WO2021145807A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
WO2014058359A1 (en) * 2012-10-09 2014-04-17 Yuji Teramura Method of coating and encapsulation of cells and cell aggregates with thick and stable polymer membrane
BR112021009984A2 (pt) * 2018-11-30 2021-08-17 Icoat Medical Ab tratamento de órgão ex vivo com moléculas de peg-fosfolipídeos

Also Published As

Publication number Publication date
US20220401566A1 (en) 2022-12-22
AU2020423624A1 (en) 2022-05-26
JP2023513656A (ja) 2023-04-03
IL292335A (en) 2022-06-01
EP4090375A1 (en) 2022-11-23
CA3157794A1 (en) 2021-07-22
BR112022009681A2 (pt) 2022-08-09
CN114761043A (zh) 2022-07-15
WO2021145807A1 (en) 2021-07-22
EP4090375A4 (en) 2024-10-02
KR20220127808A (ko) 2022-09-20

Similar Documents

Publication Publication Date Title
ES2549858T3 (es) Formas de dosificación resistentes al reflujo gástrico
TWD218793S (zh) 手機
BRPI0515973B8 (pt) kit para produzir um gel de alginato, composição para preparar um gel e uso
CN112120994A (zh) 一种紧致弹力精华液及其制备方法和应用
AU5811001A (en) Cxcr4 antagonist treatment of hematopoietic cells
DK1578350T3 (da) Sammensætninger med gel-coating med depotvirkning
DE60227789D1 (de) Vorläufer für kubische flüssigkristalline phase
CL2020001369A1 (es) Composición adecuada para usar como agroquímico, que comprende un componente de micropartícula y un agente activo de alta potencia encapsulado en la micropartícula. (divisional solicitud 201701964)
MX2022006021A (es) Peg-lipido.
UA87513C2 (ru) Фармацевтическая композиция, содержащая дроспиренон и этинилэстрадиол
CN110269818A (zh) 用于护肤品的组合物
MX2022012578A (es) N-cianopirrolidinas con actividad como inhibidores de usp30.
MX2023012363A (es) Composiciones de anticuerpos anti-tslp y usos de las mismas.
BR112022024794A2 (pt) Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose
MX337850B (es) Lipoatrofia cosmetica medicinal.
CN110464700A (zh) 一种Triple屏障修复分子组合方法
IL172786A (en) A medicinal product containing a biologically active peptide consisting of tyrosil-caryl-valine (ysv), and its uses
IL307842A (en) Methods and preparations for the treatment of glioblastoma
JP1728089S (ja) 充電ステーション
JP1728090S (ja) 充電ステーション
MX2022015254A (es) N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30.
WO2021072127A3 (en) Engineered trimeric cd70 proteins and uses thereof
CN1699453A (zh) 高负离子粉、电气石粉的应用
CN107397704A (zh) 一种具有光润亮采去黄气功效的组合物及其面膜
CN106137891A (zh) 一种富含海洋生物添加剂的美白面膜